Angion Biomedica Corp logo

ANGN

Angion Biomedica Corp

$1.02

Earnings Summary

Revenue
$1.65Mn
Net Profits
$-14.24Mn
Net Profit Margins
-864.08%

Highlights

Revenue:

Angion Biomedica Corp’s revenue jumped 344.2% since last year same period to $1.65Mn in the Q1 2022. On a quarterly growth basis, Angion Biomedica Corp has generated -93.65% fall in its revenue since last 3-months.

Net Profits:

Angion Biomedica Corp’s net profit jumped 61.19% since last year same period to $-14.24Mn in the Q1 2022. On a quarterly growth basis, Angion Biomedica Corp has generated -195.63% fall in its net profits since last 3-months.

Net Profit Margins:

Angion Biomedica Corp’s net profit margin jumped 91.26% since last year same period to -864.08% in the Q1 2022. On a quarterly growth basis, Angion Biomedica Corp has generated -1605.38% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Angion Biomedica Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.46
EPS Estimate Current Year
-0.46

Highlights

EPS Estimate Current Quarter:

Angion Biomedica Corp’s earning per share (EPS) estimates for the current quarter stand at -0.46 - a -6.98% fall from last quarter’s estimates.

EPS Estimate Current Year:

Angion Biomedica Corp’s earning per share (EPS) estimates for the current year stand at -0.46.

Key Ratios

Key ratios of the Angion Biomedica Corp post its Q1 2022 earnings

Earning Per Share (EPS)
-0.48
Return on Assets (ROA)
-0.16
Return on Equity (ROE)
-0.35
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Angion Biomedica Corp’s earning per share (EPS) jumped 69.23% since last year same period to -0.48 in the Q1 2022. This indicates that the Angion Biomedica Corp has generated 69.23% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Angion Biomedica Corp’s return on assets (ROA) stands at -0.16.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Angion Biomedica Corp’s return on equity (ROE) stands at -0.35.

Dividend Per Share (DPS):

Angion Biomedica Corp declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-16
-0.43
-0.48
-11.63%

Company Information

Angion Biomedica Corp. is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic currently being evaluating in a Phase 3 registration trial for delayed graft function in patients undergoing deceased donor kidney transplantation, a Phase 2 trial in cardiac-surgery associated acute kidney injury, and a Phase 2 trial in patients with COVID-19 related pneumonia at high risk for acute respiratory distress syndrome. Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.

Organisation
Angion Biomedica Corp
Employees
53